Anna Azvolinsky, PhD


Evolving Role of Lymph Node Biopsies After Neoadjuvant Therapy for Breast Cancer

March 23rd 2015

OncLive spoke with Kelly K. Hunt, MD, about how breast cancer interventions have progressed in the adjuvant and neoadjuvant setting and about the role of sentinel lymph node dissection in the neoadjuvant setting.

Carey Offers Views on Evolving Chemotherapy Options-and Beyond-in TNBC

March 5th 2015

OncLive spoke with Lisa A. Carey, MD, professor at the University of North Carolina Chapel Hill, about recent developments for patients with triple-negative breast cancer.

Ceritinib Demonstrates Durable Response in ALK-Positive Lung Cancer

August 7th 2014

The second-generation oral ALK inhibitor ceritinib (Zykadia; LDK378) demonstrated rapid and durable responses in patients with ALK-positive, metastatic, non–small cell lung cancer (NSCLC)-regardless of whether they had been previously treated with crizotinib-achieving overall response rates of 60% or more in each subgroup of patients who had received zero to three prior therapies for their advanced lung cancer.

Frontline Nivolumab Leads to Early, Durable Responses in NSCLC

July 25th 2014

One-third (30%) of chemotherapy-naïve non–small cell lung cancer (NSCLC) patients treated with nivolumab, an anti-PD-1 immune checkpoint antibody, responded to treatment in a phase I study.

Promising Biomarkers Emerging Across the Spectrum of Prostate Cancer Care

June 12th 2014

Researchers are making progress in identifying biomarkers and developing assays that will help clinicians improve the management of patients with prostate cancer from screening strategies to making therapy choices

2014 NCCN Guideline Updates: Experts Highlight New Recommendations for Clinical Practice

June 6th 2014

At the recent National Comprehensive Cancer Network (NCCN) 19th Annual Conference, experts discussed this year's updates to the NCCN Clinical Practice Guidelines in Oncology. The meeting also included reviews of NCCN Task Force reports on issues in supportive care. We asked eleven NCCN panel members to select the most significant updates and insights presented at the conference.

Treatment Landscape for Mantle Cell Lymphoma Continues to Evolve

April 16th 2014

Lymphoma expert Andre Goy, MD, provides insight into the rapidly changing treatment landscape for patients with mantle cell lymphoma.

Younger Patients With ALL Could Bypass a Transplant

March 31st 2014

The role of allogeneic transplant in the treatment of adult patients with acute lymphoblastic leukemia (ALL) is evolving as a result of new studies providing evidence of the efficacy of an improved chemotherapy regimen

Growing Role for Androgen-Targeting Therapies in CRPC

March 17th 2014

A new generation of agents that target androgen synthesis and AR signaling have provided proof of concept and robust data to support the hypothesis that the androgen pathway remains an important factor throughout the management of CRPC.

New Developments on Horizon in HER2-Positive Breast Cancer

March 10th 2014

In the last decade, there have been tremendous improvements in the treatment of HER2-positive breast cancer with new HER2-targeted agents improving survival in both the adjuvant and metastatic settings.

TKI Treatment Choices in mRCC Often Hinge on Dosing, Toxicities

January 27th 2014

During the past decade, several oral tyrosine kinase inhibitors targeting the vascular endothelial growth factor have been approved for the first-line treatment of metastatic renal cell carcinoma.

Latest Data Further Support Ibrutinib's Efficacy in CLL

December 11th 2013

Several trials of ibrutinib, an oral BTK inhibitor, either alone or in combination with currently used therapies for patients with chronic lymphocytic leukemia were presented at the 55th Annual Meeting of the American Society of Hematology.

RCC Care Evolving With Targeted and Novel Agents

December 4th 2013

With seven targeted therapies approved for metastatic renal cell carcinoma, researchers and drug developers are now focusing on understanding the best way to sequence these therapies and on identifying predictive biomarkers of response.

Next Generation ALK Inhibitors Poised to Become Standard of Care for Crizotinib-Resistant Patients

November 11th 2013

Next-generation ALK inhibitors are being developed to address the unmet need of patients with non-small cell lung cancer who are becoming resistant to crizotinib.

Targeted Therapies Explored in Small Cell Lung Cancer

November 11th 2013

While targeted and immunotherapy drugs have recently shown promise in non-small cell lung cancer (NSCLC), similar developments in small cell lung cancer (SCLC) have not materialized.

Novel Two-Step Immunotherapy Shows Promise in Early-Stage Ovarian Cancer Study

July 9th 2013

A two-step immunotherapy approach consisting of adoptive T-cell therapy and a dendritic cell vaccine has shown activity in a phase I advanced ovarian cancer clinical trial.

Use of Personalized Medicine to Select Adjuvant Breast Cancer Therapy

April 17th 2013

Clinical trials are under way that may change the way risk of recurrence is assessed for early-stage breast cancer patients, allowing for individualization of therapy.

New Oral Androgen Receptor Pathway Agents Are Changing the Way Prostate Cancer Is Treated

January 18th 2013

The treatment of late-stage prostate cancer is shifting; with the approval of two new oral agents there are now more options for men with metastatic prostate cancer then just two years ago.

Is There a Best Adjuvant Chemotherapy Regimen for Breast Cancer?

May 11th 2012

Three prominent breast cancer clinicians and researchers share their opinions on adjuvant anthracyclines, fluoropyrimidines, and taxane agents for women with early breast cancer.

Long-Term Breast Cancer Patient Follow-Up Care: Money Well Spent?

May 8th 2012

J. Michael Dixon, MBChB, MD, and Patrick I. Borgen, MD, discuss the pros and cons of long-term clinical follow-up care of patients with breast cancer.